Neurokinin receptor antagonists for the treatment of menopausal vasomotor symptoms: Efficacy, safety, and impact on sleep and quality of life
DOI:
https://doi.org/10.33448/rsd-v15i10.51785Keywords:
Menopause, Vasomotor symptoms, Hot flashes, Neurokinin, Fezolinetant, Elinzanetant.Abstract
Vasomotor symptoms are among the most common manifestations of the menopausal transition and may impair sleep, quality of life, and functional capacity. Although hormone therapy is effective, its use may be limited by contraindications, the need for caution, or patient preference, favoring the development of nonhormonal alternatives. This study aimed to analyze the available evidence on the efficacy and safety of neurokinin receptor antagonists for the treatment of menopause-associated vasomotor symptoms, with emphasis on fezolinetant and elinzanetant, as well as to evaluate their effects on symptom frequency and severity, sleep, and quality of life. An integrative literature review was conducted through PubMed/MEDLINE, covering publications from January 2020 to September 2026, prioritizing randomized clinical trials and following PRISMA 2020 recommendations. The studies showed that both drugs significantly reduce the frequency and severity of vasomotor symptoms compared with placebo and provide additional benefits regarding sleep and quality of life. Fezolinetant demonstrated efficacy in women considered unsuitable for hormone therapy, whereas elinzanetant showed favorable results in women receiving endocrine therapy for breast cancer. These drugs represent effective nonhormonal alternatives, although direct comparative trials and additional long-term safety data are still needed.
References
Avis, N. E., Crawford, S. L., Greendale, G., et al. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine, 175(4), 531–539. doi: 10.1001/jamainternmed.2014.8063.
Baker, F. C., Joffe, H., Soares, C. N., et al. (2026). Elinzanetant in postmenopausal women with sleep disturbance: Results from the randomized, phase II NIRVANA study. Sleep, zsag208. doi: 10.1093/sleep/zsag208.
Cano, A., Nappi, R. E., Santoro, N., et al. (2024). Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG: An International Journal of Obstetrics & Gynaecology, 131(9), 1296–1305. doi: 10.1111/1471-0528.17773.
Cardoso, F., Parke, S., Brennan, D. J., et al. (2025). Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer. New England Journal of Medicine, 393(8), 753–763. doi: 10.1056/NEJMoa2415566.
Fraser, G. L., Lederman, S., Waldbaum, A., Kroll, R., Santoro, N., Lee, M., Skillern, L., & Ramael, S. (2020). A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause, 27(4), 382–392. doi: 10.1097/GME.0000000000001510.
Gombert-Labedens, M., Vesterdorf, K., Fuller, A., Maloney, S. K., & Baker, F. C. (2025). Effects of menopause on temperature regulation. Temperature, 12(2), 92–132. doi: 10.1080/23328940.2025.2484499.
Johnson, K. A., Martin, N., Nappi, R. E., et al. (2023). Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: A phase 3 RCT. Journal of Clinical Endocrinology & Metabolism, 108(8), 1981–1997. doi: 10.1210/clinem/dgad058.
Lederman, S., Ottery, F. D., Cano, A., et al. (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): A phase 3 randomised controlled study. The Lancet, 401(10382), 1091–1102. doi: 10.1016/S0140-6736(23)00085-5.
Neal-Perry, G., Cano, A., Lederman, S., et al. (2023). Safety of fezolinetant for vasomotor symptoms associated with menopause: A randomized controlled trial. Obstetrics & Gynecology, 141(4), 737–747. doi: 10.1097/AOG.0000000000005114.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. doi: 10.1136/bmj.n71.
Panay, N., Joffe, H., Maki, P. M., et al. (2025). Elinzanetant for the treatment of vasomotor symptoms associated with menopause: A phase 3 randomized clinical trial. JAMA Internal Medicine, 185(11), 1319–1327. doi: 10.1001/jamainternmed.2025.4421.
Pereira, A. S., et al. (2018). Metodologia da pesquisa científica. Editora da UFSM. https://orcid.org/0000-0002-9813-0457
Pinkerton, J. V., Simon, J. A., Joffe, H., et al. (2024). Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA, 332(16), 1343–1354. doi: 10.1001/jama.2024.14618.
Prague, J. K., Roberts, R. E., Comninos, A. N., et al. (2017). Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: A phase 2, randomised, double-blind, placebo-controlled trial. The Lancet, 389(10081), 1809–1820. doi: 10.1016/S0140-6736(17)30823-1.
Rance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A., & Krajewski-Hall, S. J. (2013). Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes. Frontiers in Neuroendocrinology, 34(3), 211–227. doi: 10.1016/j.yfrne.2013.07.003.
Risemberg, R. I. C., Wakin, M., & Shitsuka, R. (2026). Qualitativa, quantitativa ou quali-quantitativa: Como identificar de modo rápido a abordagem de um artigo científico? E-Acadêmica, 7(2), e0172702. https://doi.org/10.52076/eacad-v7i2.702
Santoro, N., Waldbaum, A., Lederman, S., et al. (2020). Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: Results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause, 27(12), 1350–1356. doi: 10.1097/GME.0000000000001621.
Santoro, N., Nappi, R. E., Neal-Perry, G., English, M., King, D. D., Yamaguchi, Y., & Ottery, F. D. (2024). Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: Effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Menopause, 31(4), 247–257. doi: 10.1097/GME.0000000000002340.
Schaudig, K., Wang, X., Bouchard, C., et al. (2024). Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: Phase 3b randomised controlled trial. BMJ, 387, e079525. doi: 10.1136/bmj-2024-079525.
Shapiro, M. C. M., Wu, X., Wang, X., et al. (2025). Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy. Maturitas, 193, 108159. doi: 10.1016/j.maturitas.2024.108159.
Simon, J. A., Anderson, R. A., Ballantyne, E., et al. (2023). Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: A dose-finding clinical trial (SWITCH-1). Menopause, 30(3), 239–246. doi: 10.1097/GME.0000000000002138.
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of Business Research, 104, 333–339. https://doi.org/10.1016/j.jbusres.2019.07.039
Sterne, J. A. C., Savović, J., Page, M. J., et al. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. doi: 10.1136/bmj.l4898.
The North American Menopause Society. (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573–590. doi: 10.1097/GME.0000000000002200.
Torres, E., Wall, E. G., & Navarro, V. M. (2026). Neurokinin receptor antagonists for vasomotor symptoms: From KNDy neurons to clinical translation. Nature Reviews Endocrinology, 22(7), 387–403. doi: 10.1038/s41574-026-01247-8.
U.S. Food and Drug Administration. (2024). FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Drug Safety Communication. A comunicação foi publicada em setembro de 2024 e atualizada em dezembro de 2024 com a inclusão de Boxed Warning.
U.S. Food and Drug Administration. (2025). Lynkuet (elinzanetant) capsules: Prescribing information. Initial U.S. Approval: 2025. Revised October 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Rafael Marques Braga, Maria Clara Peres de Castelo Branco, Ana Laura Castilho Martins, Ana Júlia Aires Ribeiro Lopes, Isis Parreira Neves, Laura Maria Santos Abdala, Laura Manoela Siqueira Costa

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
